Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer

NCT02833766 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
48
Enrollment
OTHER
Sponsor class

Stopped the trial was prematurely terminated as per SAKK board decision from 14th of November 2020. The trial is to be terminated after primary endpoint is reached.

Conditions

Interventions

Sponsor

Swiss Cancer Institute